A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer

Trial Title: A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer

NCT ID: NCT06512051

Condition: Advanced or Metastatic Non-small Cell Lung Cancer

Conditions: Official terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Carboplatin

Study type: Interventional

Study phase: Phase 1/Phase 2

Overall status: Recruiting

Study design:

Allocation: N/A

Intervention model: Single Group Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Drug
Intervention name: SHR-A2102；Adebrelimab；Cisplatin/ Carboplatin
Description: Drug: SHR-A2102 Drug: Adebrelimab Drug: Cisplatin/ Carboplatin
Arm group label: Treatment group A

Summary: The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with Adebrelimab with or without other Antitumor Therapy in Advanced or Metastatic Non-small cell lung Cancer. To explore the reasonable dosage of SHR-A2102 for Advanced or Metastatic Non-small cell lung Cancer

Criteria for eligibility:
Criteria:
Inclusion Criteria: 1. Have the ability to give informed consent, have signed informed and able to comply with the treatment plan to visit the tests and other procedural requirements； 2. The age of signing the informed consent is 18 -70 years, regardless of gender； 3. Provide archived or fresh tumor tissue for vendor test; 4. At least one measurable lesion according to RECIST v1.1 criteria； 5. Subjects with pathology confirmed locally advanced unresectable or metastatic non-small cell lung squamous cell carcinoma; 6. The ECOG score is 0 or 1； 7. Expected survival ≥12 weeks 8. Good level of organ function 9. Male subjects whose partners are women of childbearing age and female subjects who are fertile are required to use highly effective contraceptive methods. Exclusion Criteria: 1. Active or symptomatic brain metastases. 2. With the exception of patients diagnosed with any other malignancy, except those who have achieved complete remission at least 5 years prior to screening and have ended adjuvant therapy, can be treated locally and have a clear medical record of cure, such as basal cell or squamous cell carcinoma of the skin, superficial bladder cancer in situ, carcinoma in situ of the cervix, breast ductal carcinoma in situ, and papillary carcinoma of the thyroid. 3. Moderate or severe ascites with clinical symptoms, unable to control or moderate or above pleural effusion and pericardial effusion. 4. Patients with uncontrolled tumor-related pain . 5. Have antitumor therapy was received 4 weeks before the start of the study. 6. Perform non-chest radiation therapy with >30Gy within 28 days before dosing, chest radiation therapy with >30Gy within 24 weeks before first dosing, and radiation therapy with ≤30Gy within 14 days before first dosing. 7. Subjects who are participating in another clinical study or whose first dose is less than 4 weeks from the end of the previous clinical study (last dose), or the 5 half-life of the investigational drug, whichever is shorter. 8. Surgical procedures requiring tracheal intubation and general anesthesia were performed within 28 days prior to the initial study, diagnostic or superficial surgery was performed within 7 days prior to the initial study, or elective surgery was expected during the trial period. 9. Toxicity and/or complications of previous antitumor therapy did not return to NCI-CTCAE level ≤1 or exclusion criteria 10. Systemic immunosuppressive therapy was administered within 14 days prior to the first study. 11. Subjects with a prior history of interstitial pneumonia/non-infectious pneumonia requiring hormone therapy, and currently known or suspected interstitial pneumonia/non-infectious pneumonia. 12. The presence of any active, known or suspected autoimmune disease. 13. Subjects with severe cardiovascular and cerebrovascular diseases. 14. Subjects who had a severe infection within 28 days prior to the first dose 15. Active hepatitis B or active hepatitis C. 16. Patients with active pulmonary tuberculosis within 1 year prior to enrolment. 17. Clinically significant bleeding symptoms or significant bleeding tendency occurred within 1 month before the first medication 18. History of immune deficiency 19. Live attenuated vaccines were used within 28 days prior to initial study administration or during the expected study treatment； 20. Female subjects who are pregnant or plan to become pregnant during the study period. 21. Uncontrollable mental illness and other conditions known to affect the completion of the study process, such as alcohol, drug or substance abuse, and criminal detention. 22. Per the investigator's judgment, there are any other circumstances that may increase the risk of participating in the study, interfere with the study results, or make participation in the study inappropriate.

Gender: All

Minimum age: 18 Years

Maximum age: 70 Years

Healthy volunteers: No

Locations:

Facility:
Name: Chinese People's Liberation Army General Hospital

Address:
City: Beijing
Country: China

Status: Recruiting

Investigator:
Last name: Yi Hu
Email: Principal Investigator

Start date: July 30, 2024

Completion date: October 2026

Lead sponsor:
Agency: Shanghai Hengrui Pharmaceutical Co., Ltd.
Agency class: Industry

Source: Shanghai Hengrui Pharmaceutical Co., Ltd.

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT06512051